Dostarlimab produces sustained complete responses in dMMR rectal cancer study
In plain English
The 30-second version
What happened?
In mismatch repair-deficient rectal cancer specifically, dostarlimab produced a high rate of clinical complete response — most of it sustained at 12 months, with 92% two-year recurrence-free survival across the total analysis — supporting a nonoperative-management approach for this molecularly defined subgroup.
Why does it matter?
A rare example of a systemic therapy alone producing sustained complete responses sufficient to consider avoiding surgery/radiation — but strictly bounded to a specific biomarker-defined population.
What does this not prove?
This does not apply to rectal cancer generally, is not evidence for mismatch repair-proficient (the majority of) rectal cancers, and a 92% two-year recurrence-free survival rate is not the same claim as a proven long-term cure — longer follow-up is what would establish that.
Keep reading for evidence stage, limitations, study details, and sources.
An updated publication on dostarlimab in mismatch repair-deficient (dMMR) / microsatellite instability-high (MSI-H) rectal cancer reports sustained complete responses, studied as a nonoperative-management/organ-preservation approach. Updated primary publication: PMID 40293177, https://pubmed.ncbi.nlm.nih.gov/40293177/, DOI https://doi.org/10.1056/NEJMoa2404512. Trial registry: https://clinicaltrials.gov/study/NCT04165772. Earlier primary paper: PMID 35660797, https://pubmed.ncbi.nlm.nih.gov/35660797/. This result applies SPECIFICALLY to mismatch repair-deficient disease — it must never be generalized to rectal cancer broadly, and headline/summary language must not use unqualified phrasing implying the cancer ‘vanishes’ without the dMMR/MSI-H qualifier attached. [Identifiers as supplied, attributed to independent verification outside this environment — not independently re-verified live here.]
Population / Applicability
Studied in: Mismatch repair-deficient (dMMR) / microsatellite instability-high (MSI-H) rectal cancer — never generalized to rectal cancer broadly. (Unspecified)
Applies specifically to dMMR/MSI-H disease, a molecularly defined subset of rectal cancer. Any headline/summary must retain the dMMR/MSI-H qualifier, must preserve the distinction between response / sustained response / organ preservation / long-term cure, and must not use the phrase "cancer vanishes" or equivalent unqualified framing. Two-year recurrence-free survival is not the same claim as a long-term cure.
Full evidence details
- Study design
- Non-randomized trial
- Sample size
- 117
Funding & Conflicts
Funded by Swim Across America and other sources listed in the publication (exact full funding list not specified by the frozen source — confirm the complete disclosure against the publication during human review).
Guideline positions
Guideline
- Position
- Not addressed
- Last verified
- 2026-08-11
Primary evidence supporting this story
- Updated primary publication, dostarlimab dMMR rectal cancer (NEJM) (opens in a new tab) (Peer-reviewed paper) [Peer-reviewed] 10.1056/NEJMoa2404512 Primary source DOI 10.1056/NEJMoa2404512, PMID 40293177
Updated primary publication, dostarlimab dMMR rectal cancer (NEJM). DOI 10.1056/NEJMoa2404512, PMID 40293177.
Additional context
- Earlier primary paper (no DOI supplied by the frozen source) (opens in a new tab) (Peer-reviewed paper) [Peer-reviewed] 35660797 PMID 35660797
Earlier primary paper (no DOI supplied by the frozen source). PMID 35660797.
- Trial registry (opens in a new tab) (Clinical-trial registry) NCT04165772 NCT04165772
Trial registry. NCT04165772.
Last reviewed
Dostarlimab produces sustained complete responses in dMMR rectal cancer study
https://cancerdiscoveries.com/discoveries/dostarlimab-produces-sustained-complete-responses-in-dmmr-rectal-cancer-study/
Research type: Emerging Clinical
What This Means
In mismatch repair-deficient rectal cancer specifically, dostarlimab produced a high rate of clinical complete response — most of it sustained at 12 months, with 92% two-year recurrence-free survival across the total analysis — supporting a nonoperative-management approach for this molecularly defined subgroup.
What This Doesn't Mean
This does not apply to rectal cancer generally, is not evidence for mismatch repair-proficient (the majority of) rectal cancers, and a 92% two-year recurrence-free survival rate is not the same claim as a proven long-term cure — longer follow-up is what would establish that.
Why It Matters
A rare example of a systemic therapy alone producing sustained complete responses sufficient to consider avoiding surgery/radiation — but strictly bounded to a specific biomarker-defined population.
Primary sources
- Updated primary publication, dostarlimab dMMR rectal cancer (NEJM) — https://doi.org/10.1056/NEJMoa2404512 (DOI 10.1056/NEJMoa2404512, PMID 40293177)
Date verified: 2026-08-11
Correction status: No correction or retraction